Pharma companies need to take greater ownership to make sure data quality and governance is accomplished - and it is important to keep in mind the ethics of AI use will remain front and centre for the pharma industry.
In a landmark development poised to reshape the landscape of medical diagnostics, the US Food and Drug Administration (FDA) has officially sanctioned Prenosis' pioneering artificial intelligence (AI) tool designed for the early detection of sepsis.
In an overwhelming response to the news that SimBioSys and General Inception had joined forces to use advanced AI and biophysical modeling, to gain deeper insights into tumor biology, the industry has spoken.
David Menzies is the executive director of technology solutions at ICON, a company providing outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device, and government and public health organisations.
Denmark says it is poised to revolutionize its technological landscape through a collaboration with multinational corporation NVIDIA, aimed at establishing a national center for AI innovation.
In the fast-evolving landscape of clinical trials, technological advancements play a vital role in streamlining processes, enhancing efficiency, and ultimately improving patient outcomes.
Cresset, a leading provider of integrated in silico solutions for drug discovery, announced last month (February 21) a global collaboration with Enamine, one of the front providers of chemical building blocks and drug discovery services.
By Progressive data analytics platform bioinformatics launched by Metabolon
Metabolon, Inc., a prominent figure in metabolomics solutions, has launched a seminal integrated bioinformatics platform, aiming to redefine metabolomics analysis in life sciences research.
In the fast-evolving landscape of healthcare and pharmaceuticals, the role of technology, particularly artificial intelligence (AI), is becoming increasingly prominent.
Creating artificial intelligence to understand medical conditions, and not just the English language, sounds far-fetched, but this is what one CEO is achieving with an impressive foundational innovation.
By ArisGlobal's new GenAI council sitting for first time this month
Life sciences technology company ArisGlobal, has announced the formal charter for the new generative AI Council, which will sit for the first time this month in a bid to advance life sciences innovation.
Always the buzz theme at pharma conferences, the subject of artificial intelligence (AI) continues to crop up more and more frequently. Naturally with more and more people using it for work, new regulations on data use and management are starting to appear....
OM1 says it wants to stand at the helm of a healthcare revolution, fostering an integrated approach to generating and utilizing real-world evidence (RWE), reshaping the foundation of healthcare.
Yesterday (January 22), Saama announced the release of several ‘groundbreaking’ features within its AI-driven platform, including generative AI (GenAI) chat and interactive review listings (IRL), that it says create a workflow-driven environment for cross-functional...
WNS supports the research and brand teams of more than 30 life sciences companies. The company believes its comprehensive pharma market research capabilities help clients in assimilating information from various data sources.
Clinical data management is a vital phase in clinical research, that should lead to the generation of high-quality, reliable, and statistically sound data from clinical trials.
Informatics software developer supporting R&D, ACD/Labs, has formed a collaboration with MilliporeSigma, the US and Canada Life Science business of Merck KGaA.
Gen Li is president and founder of Phesi, and OSP was delighted to speak to him to discuss the evolution of data management in clinical development and how intelligent data use can reduce clinical trial cancellations, minimise protocol amendments, and...
The pharmaceutical industry in 2023 has seen many investments, partnerships, acquisitions and more. As the year ends, industry leaders give the biggest trends to look for in 2024, with artificial intelligence being a hot topic.
The drug discovery specialist Anagenex has sealed a collaboration pact with Nimbus Therapeutics to co-develop small molecule drugs with the help of artificial intelligence (AI).
A portfolio company created and incubated by Apple Tree Partners (ATP) has raised $52 million in series A funding to enable it to rapidly discover novel small molecule therapeutics.
Patient centric, healthcare data tech company, SEQESTER says it can now deliver real-time and real-world data layering in artificial intelligence (AI) to accelerate drug discovery, thanks to its partnership with Atropos Health.
Science and technology giant, Merck, has launched its first software-as-a-service (SaaS) platform that it says bridges the gap between virtual molecule design and real-world manufacturability.
Today, world-leading generative artificial intelligence (AI) company for life sciences, Yseop, is celebrating its involvement in more than 150 clinical trials with pharma giants around the world.
OSP had a great conversation with Mike Connell, chief operating officer, at Enthought. The discussion centered around aritificial intelligence (AI) which have been the buzzwords in pharma and a number of other industries for at least the last year.
An exciting new instrument that will help identify promising drug targets for academia and the pharma industry has been unveiled in Australia by The Monash Institute of Pharmaceutical Sciences (MIPS).
OSP had a discussion with Tracy Curley, CEO of iSpecimen, and Eric Langlois, chief revenue officer of iSpecimen and Michael Howell,founder of Mountaineer Biosciences, Inc. to discuss a number of issues those working in precision medicine still face.
Excessive costs cost and time to market in clinical trials could soon be eliminated thanks to the addition of a patient access store (PAS) to Phesi's trial accelerator platform.
The Gen AI revolution promises to redefine various industries, with the life sciences sector at the forefront of this transformation. OSP had the chance to speak to Tarun Mathur, CEO at Indegene, who was keen to allay many of the fears those in the industry...
Saama, a provider of artificial intelligence (AI) based solutions, announced today (October 17) that it has formed a multi-year agreement with biopharma giant, AstraZeneca.
A new generative artificial intelligence (AI) tool has been launched by H1, a global healthcare data company and will have a 'profound impact on clinical trial diversity'.
Built upon seven years of real-world patient journey data, Belong.Life has recently announced the launch of its software as a service (SaaS)-based conversational artificial intelligence (AI) cancer clinical trial matching platform.
HumanFirst, a cloud-based software company accelerating patient-centered drug development through AI, has announced the launch of its precision measures platform.
The UK startup Intelligent OMICS (Intellomx) has launched a collaboration with Johnson & Johnson’s pharmaceutical company Janssen to use artificial intelligence (AI) to discover drug targets for the treatment of blood cancer.
Andrew MacGarvey is chief operating officer (COO) of Phastar. We caught up with him earlier in the summer at DIA Global in Boston to discuss the company’s origins, opportunities for big analytical data DCTs, artificial intelligence and machine learning...
More people are talking about mental illness than ever before. However, despite increased awareness, it remains one of the most neglected areas of public health globally, with research and quality of care lagging behind physical health conditions.
QuantHealth announced it has raised a $15 million series A funding round today (August 22) for its clinical simulator that can predict how a patient will respond to treatment in a clinical trial.
Another company OSP was lucky enough to catch up with at DIA Global in Boston this year, was well-established generative artificial intelligence (AI) software company, Yseop.
A partnership between technology company Fluree and Vitality TechNet is a ‘groundbreaking effort’ to shorten timelines within the drug discovery process.
